|
1
|
Gill RS, Al-Adra DP, Nagendran J, Campbell
S, Shi X, Haase E and Schiller D: Treatment of gastric cancer with
peritoneal carcinomatosis by cytoreductive surgery and HIPEC: A
systematic review of survival, mortality, and morbidity. J Surg
Oncol. 104:692–698. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Kanat O and O'Neil BH: Metastatic gastric
cancer treatment: A little slow but worthy progress. Med Oncol.
30:4642013. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Christiansen JJ and Rajasekaran AK:
Reassessing epithelial to mesenchymal transition as a prerequisite
for carcinoma invasion and metastasis. Cancer Res. 66:8319–8326.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Klymkowsky MW and Savagner P:
Epithelial-mesenchymal transition: A cancer researcher's conceptual
friend and foe. Am J Pathol. 174:1588–1593. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Montemayor-Garcia C, Hardin H, Guo Z,
Larrain C, Buehler D, Asioli S, Chen H and Lloyd RV: The role of
epithelial mesenchymal transition markers in thyroid carcinoma
progression. Endocr Pathol. 24:206–212. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Liang Q, Li L, Zhang J, Lei Y, Wang L, Liu
DX, Feng J, Hou P, Yao R, Zhang Y, et al: CDK5 is essential for
TGF-β1-induced epithelial-mesenchymal transition and breast cancer
progression. Sci Rep. 3:29322013. View Article : Google Scholar
|
|
7
|
Zhao L, Li W, Zang W, Liu Z, Xu X, Yu H,
Yang Q and Jia J: JMJD2B promotes epithelial-mesenchymal transition
by cooperating with β-catenin and enhances gastric cancer
metastasis. Clin Cancer Res. 19:6419–6429. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Ryu HS, Park do J, Kim HH, Kim WH and Lee
HS: Combination of epithelial-mesenchymal transition and cancer
stem cell-like phenotypes has independent prognostic value in
gastric cancer. Hum Pathol. 43:520–528. 2012. View Article : Google Scholar
|
|
9
|
Hazan RB, Qiao R, Keren R, Badano I and
Suyama K: Cadherin switch in tumor progression. Ann NY Acad Sci.
1014:155–163. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Garg M: Targeting microRNAs in
epithelial-to-mesenchymal transition-induced cancer stem cells:
Therapeutic approaches in cancer. Expert Opin Ther Targets.
19:285–297. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Kalogirou C, Spahn M, Krebs M, Joniau S,
Lerut E, Burger M, Scholz CJ, Kneitz S, Riedmiller H and Kneitz B:
MiR-205 is progressively down-regulated in lymph node metastasis
but fails as a prognostic biomarker in high-risk prostate cancer.
Int J Mol Sci. 14:21414–21434. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Tucci P, Agostini M, Grespi F, Markert EK,
Terrinoni A, Vousden KH, Muller PA, Dötsch V, Kehrloesser S, Sayan
BS, et al: Loss of p63 and its microRNA-205 target results in
enhanced cell migration and metastasis in prostate cancer. Proc
Natl Acad Sci USA. 109:15312–15317. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Yi R, O'Carroll D, Pasolli HA, Zhang Z,
Dietrich FS, Tarakhovsky A and Fuchs E: Morphogenesis in skin is
governed by discrete sets of differentially expressed microRNAs.
Nat Genet. 38:356–362. 2006. View
Article : Google Scholar : PubMed/NCBI
|
|
14
|
Ason B, Darnell DK, Wittbrodt B, Berezikov
E, Kloosterman WP, Wittbrodt J, Antin PB and Plasterk RH:
Differences in vertebrate microRNA expression. Proc Natl Acad Sci
USA. 103:14385–14389. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Gregory PA, Bert AG, Paterson EL, Barry
SC, Tsykin A, Farshid G, Vadas MA, Khew-Goodall Y and Goodall GJ:
The miR-200 family and miR-205 regulate epithelial to mesenchymal
transition by targeting ZEB1 and SIP1. Nat Cell Biol. 10:593–601.
2008. View
Article : Google Scholar : PubMed/NCBI
|
|
16
|
Fassina A, Cappellesso R, Guzzardo V,
Dalla Via L, Piccolo S, Ventura L and Fassan M:
Epithelial-mesenchymal transition in malignant mesothelioma. Mod
Pathol. 25:86–99. 2012. View Article : Google Scholar
|
|
17
|
Yin WZ, Li F, Zhang L, Ren XP, Zhang N and
Wen JF: Down-regulation of microRNA-205 promotes gastric cancer
cell proliferation. Eur Rev Med Pharmacol Sci. 18:1027–1032.
2014.PubMed/NCBI
|
|
18
|
Schmittgen TD, Zakrajsek BA, Mills AG,
Gorn V, Singer MJ and Reed MW: Quantitative reverse
transcription-polymerase chain reaction to study mRNA decay:
Comparison of endpoint and real-time methods. Anal Biochem.
285:194–204. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Lee JY, Park MK, Park JH, Lee HJ, Shin DH,
Kang Y, Lee CH and Kong G: Loss of the polycomb protein Mel-18
enhances the epithelial-mesenchymal transition by ZEB1 and ZEB2
expression through the downregulation of miR-205 in breast cancer.
Oncogene. 33:1325–1335. 2014. View Article : Google Scholar
|
|
20
|
Wellner U, Schubert J, Burk UC,
Schmalhofer O, Zhu F, Sonntag A, Waldvogel B, Vannier C, Darling D,
zur Hausen A, et al: The EMT-activator ZEB1 promotes tumorigenicity
by repressing stemness-inhibiting microRNAs. Nat Cell Biol.
11:1487–1495. 2009. View
Article : Google Scholar : PubMed/NCBI
|
|
21
|
Thiery JP and Sleeman JP: Complex networks
orchestrate epithelial-mesenchymal transitions. Nat Rev Mol Cell
Biol. 7:131–142. 2006. View
Article : Google Scholar : PubMed/NCBI
|
|
22
|
Kong YW, Ferland-McCollough D, Jackson TJ
and Bushell M: microRNAs in cancer management. Lancet Oncol.
13:e249–e258. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Bartel DP: MicroRNAs: Genomics,
biogenesis, mechanism and function. Cell. 116:281–297. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Chen K and Rajewsky N: The evolution of
gene regulation by transcription factors and microRNAs. Nat Rev
Genet. 8:93–103. 2007. View
Article : Google Scholar : PubMed/NCBI
|
|
25
|
Hui A, How C, Ito E and Liu FF: Micro-RNAs
as diagnostic or prognostic markers in human epithelial
malignancies. BMC Cancer. 11:5002011. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Yanaka Y, Muramatsu T, Uetake H, Kozaki K
and Inazawa J: miR-544a induces epithelial-mesenchymal transition
through the activation of WNT signaling pathway in gastric cancer.
Carcinogenesis. 36:1363–1371. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Zhang X, Peng Y, Jin Z, Huang Q, Cheng Y,
Liu Y, Feng X, Yang M, Huang Y, Zhao Z, et al: Integrated miRNA
profiling and bioinformatics analyses reveal potential causative
miRNAs in gastric adenocarcinoma. Oncotarget. 6:32878–32889.
2015.PubMed/NCBI
|
|
28
|
Blanco-Calvo M, Calvo L, Figueroa A,
Haz-Conde M, Anton-Aparicio L and Valladares-Ayerbes M: Circulating
microRNAs: Molecular microsensors in gastrointestinal cancer.
Sensors (Basel). 12:9349–9362. 2012. View Article : Google Scholar
|
|
29
|
Dar AA, Majid S, de Semir D, Nosrati M,
Bezrookove V and Kashani-Sabet M: miRNA-205 suppresses melanoma
cell proliferation and induces senescence via regulation of E2F1
protein. J Biol Chem. 286:16606–16614. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Brabletz S and Brabletz T: The ZEB/miR-200
feedback loop - a motor of cellular plasticity in development and
cancer? EMBO Rep. 11:670–677. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Gheldof A, Hulpiau P, van Roy F, De Craene
B and Berx G: Evolutionary functional analysis and molecular
regulation of the ZEB transcription factors. Cell Mol Life Sci.
69:2527–2541. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Arumugam T, Ramachandran V, Fournier KF,
Wang H, Marquis L, Abbruzzese JL, Gallick GE, Logsdon CD, McConkey
DJ and Choi W: Epithelial to mesenchymal transition contributes to
drug resistance in pancreatic cancer. Cancer Res. 69:5820–5828.
2009. View Article : Google Scholar : PubMed/NCBI
|
